OMNICELL,INC. (NASDAQ:OMCL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February6, 2018, at a meeting of the Compensation Committee (the “Committee”) of the Board of Directors of Omnicell,Inc. (the “Company”), the Committee granted long-term equity compensation awards to the Company’s executive officers in the amounts set forth below.

(1) The exercise price of each of the stock option grants is equal to the closing price of the Company’s stock on the date of grant, February6, 2018, as reported on The NASDAQ Global Market, which was $44.25 per share. The shares subject to each of the stock option grants vest as follows: 25% of the shares subject to the grant shall vest on the first anniversary of the vesting commencement date of such grants, February6, 2019, with the remainder of the shares subject to the grant vesting in equal monthly installments over the following thirty-six months.

(2) The time-based restricted stock unit awards vest on a semi-annual basis over a period of four years commencing on June15, 2018.

(3) The performance-based restricted stock unit awards vest as follows:25% of the shares subject to the performance-based restricted stock unit awards shall vest, if at all, on the date of the Committee meeting in 2019 when the Committee reviews the Company stock performance objectives as compared to the NASDAQ Healthcare Index and certifies in writing the extent to which the objectives were met, with the remaining 75% of the shares subject to the performance-based restricted stock unit award vesting on a semi-annual basis over a period of thirty-six months commencing on June15, 2019 only if and to the extent the Committee certifies in writing that the stock performance objectives were met. The actual number of shares that vest subject to the performance-based restricted stock units may be 0%, 50% or 50% of the numbers reflected above, depending upon the Company’s performance.

About OMNICELL,INC. (NASDAQ:OMCL)

Omnicell, Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment organizes the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. Its product line includes OmniRx, SinglePointe, AnywhereRN, Omnicell and Pandora Data Analytics, Savvy Mobile Medication System, Central Pharmacy and Satellite Pharmacy Manager, Anesthesia Workstation and Advanced Interoperability products.